ENA Trademark

Trademark Overview

On Friday, November 2, 2018, a trademark application was filed for ENA with the United States Patent and Trademark Office. The USPTO has given the ENA trademark a serial number of 79251923. The federal status of this trademark filing is REGISTERED as of Tuesday, January 7, 2020. This trademark is owned by DAIICHI SANKYO COMPANY, LIMITED. The ENA trademark is filed in the Pharmaceutical Products category with the following description:

Nucleic acid medicines for use in the treatment and prevention of genetic disorders; synthetic biomolecules, namely, synthetic nucleoside, synthetic nucleotide and synthetic nucleic acid for clinical or medical use in the treatment and prevention of genetic disorders
ena

General Information

Serial Number79251923
Word MarkENA
Filing DateFriday, November 2, 2018
Status700 - REGISTERED
Status DateTuesday, January 7, 2020
Registration Number5952326
Registration DateTuesday, January 7, 2020
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 22, 2019

Trademark Statements

Goods and ServicesNucleic acid medicines for use in the treatment and prevention of genetic disorders; synthetic biomolecules, namely, synthetic nucleoside, synthetic nucleotide and synthetic nucleic acid for clinical or medical use in the treatment and prevention of genetic disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, March 4, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameDAIICHI SANKYO COMPANY, LIMITED
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressJP
Party NameDAIICHI SANKYO COMPANY, LIMITED
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressJP
Party NameDAIICHI SANKYO COMPANY, LIMITED
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressJP

Trademark Events

Event DateEvent Description
Monday, March 4, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, February 14, 2019SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, February 15, 2019LIMITATION FROM ORIGINAL APPLICATION ENTERED
Monday, March 4, 2019ASSIGNED TO EXAMINER
Wednesday, March 6, 2019NON-FINAL ACTION WRITTEN
Monday, March 18, 2019NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, April 5, 2019REFUSAL PROCESSED BY IB
Thursday, March 7, 2019NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, March 8, 2019APPLICATION FILING RECEIPT MAILED
Monday, March 18, 2019REFUSAL PROCESSED BY MPU
Tuesday, September 17, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, September 17, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, September 17, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, September 18, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 2, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, October 2, 2019NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, October 2, 2019NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Saturday, October 19, 2019NOTIFICATION PROCESSED BY IB
Tuesday, October 22, 2019PUBLISHED FOR OPPOSITION
Tuesday, October 22, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 7, 2020REGISTERED-PRINCIPAL REGISTER
Tuesday, April 7, 2020FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Saturday, April 18, 2020FINAL DISPOSITION PROCESSED
Saturday, April 18, 2020FINAL DISPOSITION NOTICE SENT TO IB
Tuesday, January 7, 2025COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Sunday, July 3, 2022NEW REPRESENTATIVE AT IB RECEIVED
Friday, May 8, 2020FINAL DECISION TRANSACTION PROCESSED BY IB

Related Keywords

synthetic genetic nucleic prevention disorders treatment acid medical clinical nucleotide